Loading viewer...
investor_presentation
Format: PDF investor_presentation
First quarter 2024 results Earnings call May 7th, 2024 CEO Philippe Kehren CFO Alexandre Blum
First quarter 2024 results
This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans,
strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation
is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and
foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product
development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes,
all-in scenario of R&D projects and other unusual items. Consequently, actual results or future events may differ materially
from those expressed or implied by such forward-looking statements.
Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any
forward-looking statements.
This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.
Safety at the heart of our operations
RIIR (Reportable Injuries and Illness per 200,000 work hours)
H-RIIR RIIR43 3 324 4
Strong FCF supported by resilient EBITDA, cost and capex discipline
51. To Solvay shareholders from continuing operations
2. From continuing operations -12% organic -14% organic
22.1% EBITDA margin 1.4x leverage2 last 12 months
Underlying Net Debt ■ Capacity expansion in France, Italy linked to SOLVAir®
bicarbonate and in China for photovoltaic grade H2O2
■ New bio-based carbon neutral Augeo® for the Americas
■ New sustainable blowing agent Alve-OneⓇ
■ First cost savings initiatives already bearing fruit
■ Inaugural €1.5bn bond placement , strengthening our
balance sheet to drive us forward Key Q1 accomplishments
footwear, building and
construction, consumer
and currency) €1 201 m in Q1 2024
positive for the first time in 7 quarters 1,355 1,363
Preview truncated — download the full document for the complete content.
Virgin Galactic 2020 Q4 Full Year Investor Update
investor_presentationinvestor_presentation
27 Pages
Virgin Galactic Holdings, Inc.
earnings
28 Pages
Karyopharm Therapeutics Investor Presentation — September 2021
investor_presentationinvestor_presentation
30 Pages
Karyopharm Therapeutics Inc.